Ensysce Biosciences (ENSC) Non-Current Deffered Revenue (2017 - 2021)

Ensysce Biosciences (ENSC) has reported Non-Current Deffered Revenue for 5 consecutive years, with $2.0 million the latest figure, recorded in Q1 2021.

• In Q1 2021, Non-Current Deffered Revenue fell 71.43% year-over-year to $2.0 million; the TTM figure through Mar 2021 stood at $2.0 million (down 71.43% YoY), while the FY2020 annual figure was $6.8 million, down 3.57% from the prior year.
• Non-Current Deffered Revenue slipped to $2.0 million in Q1 2021 per ENSC's latest filing, from $6.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $7.0 million in Q4 2017 and bottomed at $2.0 million in Q1 2021.
• Historically, Non-Current Deffered Revenue has averaged $6.6 million across 5 years, with a median of $7.0 million in 2017.
• Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue changed 0.0% — and 2021, when it tumbled 71.43%.
• Ensysce Biosciences' Non-Current Deffered Revenue stood at $7.0 million in 2017, then changed by 0.0% to $7.0 million in 2018, then changed by 0.0% to $7.0 million in 2019, then dropped by 3.57% to $6.8 million in 2020, then tumbled by 70.37% to $2.0 million in 2021.
• Business Quant data shows ENSC's Non-Current Deffered Revenue at $2.0 million in Q1 2021, $6.8 million in Q4 2020, and $7.0 million in Q3 2020.